Dr. Nadia Nalini Ramdin, MD - Danville ...

Dr. Nadia N. Ramdin

Claim this profile

Geisinger Wyoming Valley/Henry Cancer Center

Studies Parotid Gland Cancer
Studies Breast Cancer
8 reported clinical trials
18 drugs studied

Area of expertise

1Parotid Gland Cancer
Nadia N. Ramdin has run 5 trials for Parotid Gland Cancer. Some of their research focus areas include:
HER2 positive
ER positive
ER negative
2Breast Cancer
Nadia N. Ramdin has run 4 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
Stage IV

Affiliated Hospitals

Image of trial facility.
Geisinger Wyoming Valley/Henry Cancer Center
Image of trial facility.
Geisinger Medical Center

Clinical Trials Nadia N. Ramdin is currently running

Image of trial facility.

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.
Recruiting1 award Phase 231 criteria
Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A

More about Nadia N. Ramdin

Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Nadia N. Ramdin has experience with
  • Cisplatin
  • Nivolumab
  • Intensity-Modulated Radiation Therapy
  • Paclitaxel
  • Trastuzumab
  • Pertuzumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Nadia N. Ramdin specialize in?
Is Nadia N. Ramdin currently recruiting for clinical trials?
Are there any treatments that Nadia N. Ramdin has studied deeply?
What is the best way to schedule an appointment with Nadia N. Ramdin?
What is the office address of Nadia N. Ramdin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security